T2 Biosystems to launch COVID-19 test in the U.S.

By LabPulse.com staff writers

July 1, 2020 -- T2 Biosystems announced it has completed the validation of its COVID-19 molecular diagnostic test and will distribute it commercially in the U.S.

The T2SARS-CoV-2 panel provides results in fewer than two hours, utilizing a nasopharyngeal swab sample. It has sensitivity of 95% and specificity of 100%, according to T2 Biosystems.

T2 Biosystems developed the panel under a licensing agreement with the Center of Discovery and Innovation at Hackensack Meridian Health. The panel will run on the company's T2Dx instrument, which can run seven tests simultaneously, according to the company.

T2 adds coronavirus test to panels, per health network deal
T2 Biosystems has signed a worldwide licensing agreement for a rapid test developed by New Jersey-based Hackensack Meridian Health for SARS-CoV-2.
T2 Biosystems recruits Chembio's John Sperzel as new CEO
T2 Biosystems has named John Sperzel as its new president and CEO. Sperzel most recently served as president and CEO of infectious disease point-of-care...
T2 Biosystems advances new tests through BARDA funding
T2 Biosystems is accelerating the development of new direct-from-blood tests through a milestone-based funding contract with the U.S. Biomedical Advanced...
T2 stretches out globally with sepsis assays
T2 Biosystems is introducing its T2Bacteria and T2Candida whole-blood panel diagnostics in five new countries -- Estonia, Greece, Ireland, Saudi Arabia,...
Exact Sciences buys Genomic Health for $2.8B
The just-announced combination of Genomic Health and Exact Sciences will bring the Cologuard colon cancer diagnostic and Oncotype DX assay under one corporate...

Copyright © 2020 LabPulse.com

Last Updated ls 7/1/2020 3:49:12 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current